MRNA vs XFOR
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 23, 2026
MRNA
35.2
AI Score
VS
XFOR Wins
XFOR
40.7
AI Score
Investment Advisor Scores
XFOR
41score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | MRNA | XFOR | Winner |
|---|---|---|---|
| Revenue | 534.00M | 4.80M | MRNA |
| Net Income | -2.13B | -36.40M | XFOR |
| Net Margin | -397.9% | -758.3% | MRNA |
| Operating Income | -2.20B | -36.70M | XFOR |
| ROE | -31.4% | -23.4% | XFOR |
| ROA | -19.4% | -14.4% | XFOR |
| Total Assets | 10.96B | 253.06M | MRNA |
| Cash | 1.72B | 195.09M | MRNA |
| Debt/Equity | 0.09 | 0.48 | MRNA |
| Current Ratio | 2.29 | 11.30 | XFOR |
Relative Price Performance (Last 90 Days)
MRNA 1M: +11.3%
· 3M: +274.8%
XFOR 1M: +2.9%
· 3M: -16.9%
Current Technical Phase
MRNA
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (56.8% over 20 days), RSI 51
XFOR
NeutralHold
Mixed signals - no dominant trend phase, RSI 56
Fundamentals Snapshot
| Metric | MRNA | XFOR |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -42.4 | -4.2 |
| Trailing P/E | — | 150.5 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 3.5% |
| Gross Margin | -0.7% | 0.8% |
| Operating Margin | -5.6% | -1.9% |
| EPS | -8.10 | 0.02 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, XFOR is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.